Grapefruit juice contains naringin and related furanocoumarins that irreversibly inhibit CYP3A4 enzyme activity in the intestinal wall epithelium, substantially reducing presystemic first-pass metabolism of buspirone

Because buspirone normally undergoes extensive CYP3A4-mediated first-pass metabolism with low oral bioavailability, inhibition of intestinal CYP3A4 dramatically increases the fraction of each dose reaching systemic circulation. This mechanism-based inhibition destroys the intestinal CYP3A4 enzyme and requires de novo enzyme protein synthesis for recovery, which takes 24-72 hours after grapefruit ingestion. The resulting increase in buspirone bioavailability produces dose-dependent adverse effects including sedation and dizziness. Buspirone has very low oral bioavailability (approximately 4%) due to extensive CYP3A4-mediated first-pass metabolism in the intestinal wall and liver.

Grapefruit juice contains high concentrations of citric acid that alter gastric pH, creating an acidic environment that converts buspirone from its inactive salt form to its active free base

This is absorbed much more readily across the gastric mucosa. The enhanced absorption occurs specifically in the stomach rather than the small intestine, bypassing the normal enterohepatic circulation that limits buspirone's bioavailability. This pH-dependent solubility shift is specific to drugs with basic amine functional groups in their molecular structure. The effect is proportional to the volume of grapefruit juice consumed and can be mitigated by taking buspirone on a full stomach. Gastric pH alteration is not the mechanism by which grapefruit juice interacts with buspirone or other CYP3A4 substrates. The interaction is mediated by furanocoumarins that irreversibly inhibit intestinal CYP3A4 enzyme activity, reducing first-pass metabolism and increasing oral bioavailability.

Grapefruit juice induces expression of P-glycoprotein efflux transporters in the blood-brain barrier endothelium

Paradoxically increasing central nervous system penetration of buspirone by altering the directionality of P-glycoprotein transport from efflux to influx. This reversal of transporter function is unique to grapefruit furanocoumarins and results in greater CNS drug exposure without changing systemic plasma levels. The clinical implication is that standard plasma drug level monitoring would not detect this interaction because peripheral blood concentrations remain unchanged. The increased CNS exposure explains the patient's sedation and dizziness without requiring a change in overall systemic pharmacokinetics. Grapefruit juice has been shown to inhibit, not induce, intestinal P-glycoprotein, and the concept of reversing P-glycoprotein transport directionality is pharmacologically inaccurate.

Grapefruit juice contains bioflavonoids that act as competitive agonists at the 5-HT1A receptor, the same receptor subtype through which buspirone exerts its anxiolytic effects

The additive 5-HT1A stimulation from both buspirone and the grapefruit bioflavonoids exceeds the therapeutic window and produces excessive serotonergic stimulation in the raphe nuclei and hypothalamus. This pharmacodynamic interaction is proportional to the quantity of grapefruit juice consumed and occurs independently of any changes in buspirone metabolism or plasma levels. The dizziness and sedation represent early signs of serotonergic overstimulation that could progress to serotonin syndrome with continued grapefruit consumption. Grapefruit bioflavonoids do not have clinically meaningful 5-HT1A agonist activity. The interaction between grapefruit juice and buspirone is pharmacokinetic, not pharmacodynamic, mediated by furanocoumarin inhibition of intestinal CYP3A4 enzyme activity.